Related Experiment Video
Updated: Apr 16, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.6K
Neuronal hyperactivity--A key defect in Alzheimer's disease?
Marc Aurel Busche1,2,3, Arthur Konnerth1,3
1Institute of Neuroscience, Technische Universität München, München, Germany.
Summary
Alzheimer's disease (AD) may involve early neuronal hyperactivity, not just reduced activity. This finding challenges traditional views and suggests new therapeutic targets for cognitive impairment.
Area of Science:
- Neuroscience
- Pathophysiology of Alzheimer's Disease
Background:
- Traditional understanding of Alzheimer's disease (AD) attributes cognitive decline to reduced neuronal and synaptic activity.
- This perspective has guided research and therapeutic strategies for decades.
Purpose of the Study:
- To review current in vivo evidence on neuronal activity in early-stage Alzheimer's disease.
- To present a paradigm shift from hypoactivity to hyperactivity as an early hallmark of AD.
Main Methods:
- Analysis of in vivo data from mouse models and human patients.
- Electrophysiological and imaging techniques applied at multiple levels (single neurons to large-scale networks).
Main Results:
- Evidence indicates neuronal circuits are hyperactive in early stages of AD.
- Two distinct forms of AD-related neuronal hyperactivity have been identified.
- Initial insights into the synaptic mechanisms underlying this hyperactivity have been gained.
Conclusions:
- Early-stage Alzheimer's disease is characterized by neuronal hyperactivity, challenging the traditional hypoactivity model.
- This discovery represents a significant conceptual shift in understanding AD pathogenesis.
- The findings have potential implications for developing novel therapeutic strategies targeting early neuronal dysfunction.
Related Concept Videos
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Neural Regulation
45.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
45.1K
Role of Neurotransmitters in Memory
3.0K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
3.0K

